catapresan 25 mikrog
boehringer ingelheim international gmbh - klonidinhydroklorid - tablett, drasjert - 25 mikrog
nytox vet 1000 mg/ g
naqua ltd - trikainmesilat - pulver til behandlingsoppløsning til fisk - 1000 mg/ g
tricaine pharmaq 1000 mg/ g
pharmaq as, overhalla - trikainmesilat - pulver til behandlingsoppløsning til fisk - 1000 mg/ g
isemid
ceva santé animale - torasemide - high-ceiling diuretika, sulfonamider, vanlig - hunder - for behandling av kliniske tegn er relatert til hjertesvikt hos hund, blant annet lungeødem.
nyvigan kombipakning 100000 ie/ g / 100000 ie
avia pharma ab - nystatin - salve, vaginaltablett - 100000 ie/ g / 100000 ie
profender 96 mg / 24 mg
2care4 aps - prazikvantel / emodepsid - påflekkingsvæske, oppløsning - 96 mg / 24 mg
diane 2 mg / 35 mikrog
bayer ab - solna - cyproteronacetat / etinyløstradiol - tablett, drasjert - 2 mg / 35 mikrog
alofisel
takeda pharma a/s - darvadstrocel - rektal fistel - immunsuppressive - alofisel er angitt for behandling av komplekse perianale fistler hos voksne pasienter med ikke-aktive/mildt aktiv luminal crohns sykdom, når fistler har vist en utilstrekkelig respons på minst en konvensjonell eller biologisk terapi. alofisel bør brukes etter condition av fistel.
dasatinib accord
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.